Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$64.6M Buy
2,683,370
+22,589
+0.8% +$591K 0.68% 22
2026
Q1
$74.7M Buy
2,660,781
+174,969
+7% +$4.66M 0.83% 17
2025
Q4
$61.9M Buy
2,485,812
+1,750,956
+238% +$44.2M 0.8% 20
2025
Q3
$18.7M Hold
734,856
0.4% 42
2025
Q2
$17.8M Hold
734,856
0.42% 44
2025
Q1
$18.6M Hold
734,856
0.5% 39
2024
Q4
$19.5M Buy
734,856
+4,470
+0.6% +$121K 0.51% 37
2024
Q3
$21.1M Sell
730,386
-140
-0% -$4.08K 0.57% 32
2024
Q2
$20.4M Sell
730,526
-380
-0.1% -$10.5K 0.6% 30
2024
Q1
$20.3M Buy
+730,906
New +$20.3M 0.64% 28

Other funds holding PFE

Allianz's PFE Position: Q2 2026 in Review

Allianz increased its Pfizer (PFE) stake by 0.85% in Q2 2026, buying an estimated $591K and bringing the position to 2,683,370 shares worth $64.6M. The position accounts for 0.68% of the portfolio, ranked #22.

Allianz first reported a position in PFE in Q1 2024 and has held it in 10 quarters since. The position peaked at $74.7M in Q1 2026. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Allianz held 2,683,370 shares of Pfizer worth $64.6M as of Q2 2026.
  • Allianz bought 22,589 Pfizer shares in Q2 2026, an estimated $591K.
  • Pfizer made up 0.68% of Allianz's portfolio in Q2 2026, its #22 holding.
  • Allianz first reported a position in Pfizer in Q1 2024 and has held it in 10 quarters since.
  • Allianz's Pfizer position peaked at $74.7M in Q1 2026.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Allianz's 13F filing for Q2 2026, filed 10 Aug 2026.